Genentech, Inc.
NEWS
BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.
At the virtual Congress of the ECTRIMS meeting this week, multiple companies present data for ongoing studies of therapies for multiple sclerosis. BioSpace takes a look at some of the data.
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
Frederick Frank, an innovator of biotech investment who played a key role in Roche’s acquisition of Genentech and the merger that formed Bristol-Myers Squibb, has died.
Mammoth will use the funds to build and broaden its stable of next-generation CRISPR products to detect and cure various diseases.
Adaptimmune will be responsible for developing clinical T-cell candidates for the two companies through its induced pluripotent stem cell (iPSC) derived allogeneic platform.
There were a fair number of clinical trial announcements last week. Here’s a look.
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints.
JOBS
IN THE PRESS